Animal hoarding: a systematic review

Objectives: Animal hoarding is a special manifestation of hoarding disorder, characterized by the accumulation of animals and failure to provide them with minimal care. The main objective of this systematic review is to evaluate the characteristics of animal hoarding, focusing on the profile of affected individuals and the features of accumulation behavior. Methods: A systematic search of the literature was conducted in the electronic databases MEDLINE, Scopus, and LILACS until October 2022. We included case series (n ≥ 10) and cross-sectional studies assessing animal hoarding. Results: A total of 374 studies were initially retrieved. Most studies were classified as having poor quality and significant risk of bias. A total of 538 individuals with animal hoarding were evaluated. These individuals were predominantly middle-aged, unmarried women who lived alone in urban areas. Most of their residences had unsanitary conditions. Recidivism rates varied from 13-41%. Cats and dogs were the main hoarded species, mostly acquired through unplanned breeding, and disease, injury, behavioral problems, and a lack of hygiene were characreristic of their condition. Animal carcasses were found in up to 60% of the properties. Conclusion: Animal hoarding is a complex condition that requires urgent attention. More research is necessary to develop effective strategies that can save community resources, improve animal and human welfare, and prevent recidivism.

Animal Hoarding: a systematic review.

OBJECTIVE: Animal hoarding is a special manifestation of Hoarding Disorder, characterized by the accumulation of animals and failure to provide them with minimal care. The main objective of this systematic review is to evaluate the characteristics of animal hoarding with a focus on the profile of affected individuals and accumulation behavior features. METHODS: A systematic search of the literature using the electronic databases MEDLINE, SCOPUS and LILACS was conducted until October 2022. We included case series (n ≥ 10) and cross-sectional studies assessing animal hoarding. RESULTS: 374 studies were initially retrieved. Most studies were classified as poor quality and significant risk of bias. 538 individuals with animal hoarding were evaluated. These individuals were predominantly middle-aged, unmarried females who lived alone in urban areas. Most residences presented unsanitary conditions. Recidivism rates varied from 13-41%. Cats and dogs were the main hoarded species, mostly acquired through unplanned breeding and found with lack of hygiene; diseases; injuries; and behavioral problems. Animal carcasses were found in up to 60% of the properties. CONCLUSION: Animal hoarding is a complex condition that requires urgent attention. More research is necessary to develop effective strategies that can save community resources, improve animal and human welfare, and prevent recidivism.

Potential advantages of ketamine over electroconvulsive therapy in the treatment of nonrefractory severe depression in older patients with multiple medical comorbidities.

Depression in older adults with multiple medical comorbidities can contribute to clinical deterioration, and increased mortality. Electroconvulsive therapy (ECT) is the first-line treatment for these patients. This study aimed to evaluate the effectiveness and safety of subcutaneous (SC) ketamine as an alternative to ECT. We reviewed the medical records of all consecutive older inpatients with severe depression and multiple medical comorbidities who were referred for ECT but treated with SC ketamine over 1 year in our institution. Demographic data, DSM-5 diagnosis, MÅDRS score, and CGI score were analyzed. Twelve patients aged 67-94 years were included. All patients were rated as severely ill, 83% were women, with a mean of 12.6 (SD, 1.4) medical comorbidities. Remission was achieved in 75% of the intention-to-treat population and 100% of treatment completers. The number of sessions ranged from 1 to 6, and days until remission from 1 to 16. Patients remained without relapse for 8-28 months. SC ketamine was safe and well tolerated, and most adverse events were mild and transient. Although limited by the retrospective open-label design of the study and small sample size, our findings provide a potential new indication for ketamine: treatment of severe depression, not necessarily resistant to antidepressants, in older patients with multiple medical comorbidities, at risk of clinical deterioration, and referral for ECT. SC ketamine was highly effective in this population, with no relapse and good tolerance. Randomized controlled trials are needed to adequately test the use of ketamine in this specific group.

Transtorno de acumulação: uma revisão / Hoarding disorder: a review

O transtorno de acumulação (TA) pode ser definido como uma dificuldade persistente de desfazer-se de itens devido ao sofrimento associado com o descarte ou uma necessidade percebida de guardar posses a despeito de seu valor real. Tal comportamento pode resultar no acúmulo de objetos, o que compromete significativamente o uso da moradia, causando sofrimento e/ou prejuízo funcional. Os itens acumulados mais frequentemente são objetos e animais. A prevalência do transtorno é de 1,5 a 2,1% na população em geral, podendo ser maior que 6% em idosos. O TA causa riscos à saúde e à segurança dos indivíduos, especialmente dos idosos, gerando um custo relevante para a sociedade. O diagnóstico de TA é clínico e só deve ser feito após a exclusão de condições médicas gerais e outros transtornos mentais que podem levar ao acúmulo de objetos. O TA parece ser um transtorno de curso crônico e progressivo, comumente associado a comorbidades psiquiátricas. Estudos indicam a participação de fatores genéticos, familiares, cognitivos e de experiências traumáticas na etiologia do TA. A abordagem terapêutica mais estudada até o momento foram as psicoterapias, mas os resultados mostram efeito pequeno. Os estudos farmacológicos existentes são muito incipientes, não permitindo conclusões de eficácia.

Hoarding disorder can be defined as a persistent difficulty in discarding items, due to distress associated with such disposal or a perceived need to save items regardless of their actual value. Such behavior must result in the accumulation of clutter, which significantly compromises living conditions, causing distress and/or functional impairment. The most frequently hoarded items are objects and animals. The point prevalence of clinically significant hoarding was estimated to be 1.5 to 2.1% in the general population, and may exceed 6% in the elderly. HD poses a range of health and safety hazards to individuals, especially older adults, generating significant costs to society. The diagnosis of HD is clinical, and should only be established after general medical conditions and other mental disorders that can lead to accumulating behavior have been ruled out. HD appears to follow a chronic, progressive course, and is commonly associated with psychiatric comorbidities. Studies indicate that genetic, familial, cognitive, and traumatic factors are implicated in the etiology of HD. To date, psychotherapies have been the most widely studied therapeutic approaches, but the results of these studies show small effects. Research into pharmacological approaches to HD is still incipient, precluding any conclusions of efficacy

Klotho dysfunction: A pathway linking the aging process to bipolar disorder?

AIM: Although accelerated aging profile has been described in bipolar disorder (BD), the biology linking BD and aging is still largely unknown. Reduced levels and/or activity of a protein named Klotho is associated with decreased life span, premature aging and occurrence of age-related diseases. Therefore, this study was designed to evaluate plasma levels of Klotho in BD patients and controls. METHODS: Forty patients with type 1 BD and 30 controls were enrolled in this study. After clinical evaluation, peripheral blood samples were drawn and plasma levels of Klotho were measured using enzyme-linked immunosorbent assay. RESULTS: Patients with BD and controls presented similar age and sex distribution. The mean ± SD length of illness was 24.00 ± 12.75 years. BD patients presented increased frequency of clinical comorbidities in comparison with controls, mainly arterial hypertension, diabetes mellitus, and hypothyroidism. Both patients with BD in remission and in mania exhibited increased plasma levels of Klotho in comparison with controls. There was no significant difference between patients in mania and patients in remission regarding the levels of Klotho. CONCLUSION: Klotho-related pathway is altered in BD. Contrary to our original hypothesis, our sample of patients with BD presented increased plasma levels of Klotho in comparison with controls. Elevated levels of Klotho in long-term BD patients may be associated with the disorder progression. Further studies are needed to better understand the role of Klotho in BD and other mood disorders.

Depression diagnosed by the mini international neuropsychiatric interview plus (MINI) in patients with chronic obstructive pulmonary disease: relationship with functional capacity and quality of life.

BACKGROUND: The prevalence of depression in patients with chronic obstructive pulmonary disease (COPD) is associated with a worsening of prognosis. Most studies classify COPD patients as depressive or non-depressive based on symptoms, rather than on a diagnosis using specific tools. Thus, the aim of this study was to determine the impact of depression, as diagnosed by the Mini International Neuropsychiatric Interview Plus (MINI), on functional capacity estimated by the 6-minute walk test (6MWT) and unsupported upper-limb exercise test, and quality of life estimated by Saint George's Respiratory Questionnaire (SGRQ), among patients with COPD. RESULTS: Using the MINI as a diagnostic tool, 22.2 % of all patients (6.6 % of all men and 41.6 % of all women) were diagnosed with depression. No significant differences were found between depressive and non-depressive patients with regard to anthropometric measurements, lung function, functional capacity, or quality of life variables. The best models for the dependent variables representing functional capacity and quality of life revealed that the covariates SGRQTOTAL and gender (R(2) = 16.7 %) were significant in explaining the response variable for functional capacity of the upper limbs. Results also showed that age, monthly income, insomnia, and the results of a 6MWT were significant in explaining overall quality of life (R(2) = 46 %), and that the percentage of the predicted forced expiratory volume in the first second post-bronchodilator and gender were significant in explaining walking distance (R(2) = 22 %). Depression, as diagnosed by the MINI, was not significant in explaining any of the dependent variables. CONCLUSIONS: Despite a high prevalence of depression in COPD patients, especially in women, depression, as diagnosed by the MINI, was not correlated with functional capacity tests or quality of life in patients with moderate to very severe COPD in the present study. This suggests that depression identified by this diagnostic test may be more accurate than depression diagnosed by tests that evaluate symptoms, as they may be influenced by the perceptions of the patient in relation to their health.

Doença mental e estigma / Mental disease and stigma

Estima-se que 450 milhões de pessoas no mundo sofram de transtornos mentais, com elevado custo para indivíduos e sociedade. Percentual de 14% do fardo de doenças é atribuível aos transtornos neuropsiquiátricos, principalmente em decorrência da natureza crônica e incapacitante da depressão e de outros transtornos psiquiátricos comuns. Pessoas com doenças mentais graves lutam contra dois problemas: os sintomas, que interferem na autonomia, independência e qualidade de vida, e o estigma social. O estigma associado à doença mental é dos mais importantese difíceis obstáculos para a recuperação e reabilitação do indivíduo; afeta negativamente o tratamento; nega oportunidade de trabalho; impede a autonomia e a realização de objetivos de vida. É capaz de prejudicar a qualidade de vida, inclusive da família e da equipe de saúde que lida com as doenças psiquiátricas. A discriminação pode ser tão incapacitante quanto a própria doença. Além disso, viver em ambiente estigmatizante frequentemente acarreta o autoestigma, que junto com o estigma são dois obstáculos fundamentais à integração social e à vida plena em sociedade.O combate ao estigma é primordial para que o portador de doença mentalviva de forma independente e autônoma, tenha oportunidades de trabalho, persiga suas metas e usufrua de oportunidades com dignidade e plena inserção social.

It is estimated that 450 million people worldwide suffer from mental disorders, with a highcost to individuals and society. The percentage of 14% of the disease burden is attributableto neuropsychiatric disorders, mainly due to the chronic and disabling nature of depressionand other common mental disorders. People with severe mental illness fight two problems:the symptoms that interfere with their autonomy, independence, and quality of life, andthe social stigma. The stigma associated with mental illness is the most important anddifficult obstacle in the recovery and rehabilitation of the individual; it negatively affectsthe treatment; denies job opportunities; prevents autonomy and the achievement of lifegoals. It can impair the quality of life, including that of the family and the health team thatdeals with psychiatric disorders. Discrimination can be as debilitating as the disease itself.Moreover, living in a stigmatizing environment often leads to auto-stigma, which alongwith the disease stigma are two main obstacles to social integration and full life in society.Fighting the stigma is critical to the bearer of mental illness to live independently and autonomously,have job opportunities, pursue life goals, and take advantage of opportunitieswith dignity and full social integration.

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

OBJECTIVE: The purpose of this prospective study was to evaluate the effects of switching from oral risperidone to flexibly dosed oral paliperidone extended-release (ER) in Brazilian adults with schizophrenia because of lack of efficacy, intolerability, or nonadherence after a minimum trial of 30 days on adequate (labeled) doses of oral risperidone, according to individual clinical judgment. RESEARCH DESIGN AND METHODS: Subjects with Positive and Negative Syndrome Scale total scores above 78, and/or intolerable adverse effects, with risperidone received open-label paliperidone ER 3 to 12 mg daily for 26 (main phase) to 52 (extension phase) weeks. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01010776. RESULTS: The intent-to-treat (efficacy) populations comprised 213 subjects in the main phase and 159 in the extension phase. Of 213 subjects with baseline and post-baseline efficacy data, 154 (72.3%) switched from risperidone to paliperidone ER because of a lack of efficacy and 59 (27.7%) because of tolerability issues, according to individual clinical judgment. Paliperidone ER significantly (p < 0.0500) improved a broad spectrum of efficacy endpoints from baseline, as early as the first post-baseline visit (Visit 2; 4 weeks) and persisting through 26 to 52 weeks. On most efficacy endpoints, function improved from baseline to the first post-baseline visit (week 4) and remained significantly improved compared to baseline at each visit for paliperidone ER treatment, at weeks 8, 13, 26, 39, 26, and 52; data are reported herein mainly for 26 and 52 weeks compared to baseline. Significant improvements from baseline were observed for the Positive and Negative Syndrome Scale total score and subscale scores (each p < 0.0001 at 26 and 52 weeks vs. baseline); and personal and social functioning (p < 0.0001 at 26 and 52 weeks). Paliperidone ER also significantly improved health-related quality of life (Short-Form 36) from baseline, particularly on the Mental Component Summary (p = 0.0011 at 26 weeks and p = 0.0019 at 52 weeks). Treatment with paliperidone ER also significantly improved (vs. baseline) sleep quality (according to decreases on the Pittsburgh Sleep Quality Index; p < 0.0001 at each visit vs. baseline) and disease severity (Clinical Global Impression-Severity; p < 0.0001 at each visit vs. baseline). Paliperidone ER was well tolerated. Adverse events occurring in at least 10% of subjects in either phase were insomnia (14.9% in the main phase and 8.8% in the extension phase); increased body weight (10.7% and 12.6%, respectively); and anxiety (10.7% and 2.5%). Most of these adverse events were: 1) rated as mild or moderate; 2) did not prompt interventions such as paliperidone ER dose adjustment or interruption; and 3) decreased in frequency from the main to the extension phase. CONCLUSIONS: Oral paliperidone ER is a rational treatment alternative for patients with schizophrenia whose antipsychotic regimens are switched because of unsuccessful treatment with oral risperidone according to individual clinical judgment. Study limitations included the open-label study design, lack of placebo, and use of subjective clinical judgment to determine lack of efficacy, intolerability, or nonadherence with oral risperidone.

The broad autism phenotype in parents of individuals with autism: a systematic review of the literature / O fenótipo ampliado do autismo em pais de indivíduos autistas: uma revisão sistemática da literatura

The broad autism phenotype (BAP) is a milder manifestation of the defining symptoms of the syndrome in individuals without autism. This study conducted a systematic review of studies about behavioral characteristics of interpersonal relationships, communication and rigidity, as well as about three cognitive models, Theory of Mind, central coherence and executive function, in parents of individuals with autism. The indexed databases were LILACS, IBECS, Web of Science, and MEDLINE, and the studies retrieved were published between 1991 and March 2012. Parents of individuals with autism have more difficulties in interpersonal relationships and in pragmatic language use and have more rigidity traits. The inclusions of the cognitive theories in the group of BAP characteristics were inconclusive (AU)

O fenótipo ampliado do autismo (FAA) é a manifestação atenuada de características qualitativamente similares às que definem a síndrome, em indivíduos não portadores do transtorno. O objetivo deste artigo é realizar uma revisão sistemática de estudos que abordam as características comportamentais relacionadas a interação social, comunicação e rigidez, além dos modelos cognitivos Teoria da Mente (Theory of Mind, ToM), coerência central e funções executivas, em pais de indivíduos autistas. As bases de dados consultadas foram: LILACS, IBECS, Web of Science e MEDLINE; foram selecionados estudos publicados entre 1991 e março de 2012. Os resultados apontaram que os pais de indivíduos autistas possuem déficits na interação social, na linguagem pragmática e traços de rigidez. A inclusão dos modelos cognitivos do autismo no grupo de características que compõem o FAA permanece inconclusiva (AU)

Medo de cair e qualidade de vida em idosos com catarata / Fear of falling and quality of life in elderly with cataract

INTRODUÇÃO: O medo de cair é definido como baixa autoeficácia ou confiança no próprio equilíbrio para evitar quedas, causando declínio no desempenho físico e funcional, alterações no equilíbrio e na marcha dos idosos, tendo impacto negativo na qualidade de vida. Vários estudos têm identificado o déficit visual como fator contributivo para a ocorrência de quedas e do medo de cair em idosos. OBJETIVOS: Avaliar a associação entre o medo de cair e as alterações na visão funcional e na qualidade de vida relacionada à visão de idosos com catarata. MÉTODOS: Trata-se de estudo observacional com 139 idosos com catarata (71,4±6,2 anos). A qualidade de vida relacionada à visão foi avaliada pelo Visual Function Questionnaire (VFQ) e a preocupação com a possibilidade de quedas foi avaliada pela Falls Efficacy Scale International (FES-I-Brasil). RESULTADOS: Idosos que relataram algum grau de medo de cair apresentaram médias mais altas na escala FES-I-Brasil, quando comparados aos que não o relataram, indicando maior preocupação com a possibilidade de cair (p=0,000; Kruskal-Wallis). Com relação à visão funcional (VFQ) e à qualidade de vida relacionada à visão, quanto maior o medo de cair, piores eram a visão e a qualidade de vida (p=0,003; Kruskal-Wallis). CONCLUSÃO: Idosos com catarata e com relato de medo de cair apresentaram menor confiança no seu equilíbrio para evitar quedas e pior qualidade na visão funcional e na qualidade de vida relacionada à visão.

INTRODUCTION: Fear of falling is defined as low self-efficacy or self-confidence in one's own balance to avoid falls. It causes limitations in physical and functional performance, balance and walking impairment, and has negative impact on quality of life. Many research works have identified visual impairment as one of the factors that contribute to falls and fear of falling. OBJECTIVES: Evaluate the association between fear of falling and visual function impairment and the related-vision quality of life in elderly patients with cataract. METHODS: Observational study conducted with 139 elderly patients with cataract (71.4±6.2 years). Vision-related quality of life was assessed through the Visual Function Questionnaire (VFQ). Interviews were made by means of the Falls Efficacy Scale International (FES-I Brazil) to evaluate the concern with falling. RESULTS: Elderly patient with fear of falling had higher averages in FES-I-Brazil than other elderly patients (p=0.000; Kruskal-Wallis). The greater the fear of falling, the worst were the visual function (VFQ) and the related-vision quality of life (p=0,003; Kruskal-Wallis). CONCLUSION: Elderly patients with cataract and fear of falling had less self-confidence in their balance to avoid falls and worst functional vision and related-vision quality of life.

Evidências sobre a combinação de antidepressivos na depressão maior / Evidence on the combination of antidepressants in major depression

O objetivo desta revisão narrativa é avaliar as evidências científicas do emprego de combinação de antidepressivos no tratamento da depressão maior. Foram avaliadas duas modalidades de combinação: a introdução da combinação desde o início do tratamento e a associação de um segundo antidepressivo em pacientes que não apresentaram resposta satisfatória com o primeiro antidepressivo. Foram pesquisadas as principais bases de dados até outubro de 2012, sem restrição de língua (PubMed, Cochrane Library, Embase, PsycINFO, Lilacs, registros de ensaios clínicos e bancos de teses) e referências secundárias. Foram utilizadas revisões sistemáticas recentes, ensaios clínicos não contemplados pelas revisões e artigos de revisão sobre o tema. Ambas as formas de combinação de antidepressivos foram muito pouco estudadas. De maneira geral, os ensaios incluíram número muito pequeno de sujeitos e apresentaram problemas metodológicos significativos. Os resultados são controversos. As evidências existentes não permitem conclusões sólidas acerca da eficácia e tolerabilidade do emprego de associações de antidepressivos.

Dor, cinesiofobia e qualidade de Vida em pacientes com lombalgia crônica e depressão / Pain, kinesiophobia and quality of life in chronic low back pain and depression

Objetivo: Descrever características de dor, cinesiofobia e qualidade de vida em pacientes com lombalgia crônica associada a depressão. Métodos: Estudo de delineamento transversal em que foram incluídos 193 indivíduos com lombalgia crônica. A presença de depressão foi determinada pelo Inventário de Depressão de Beck, a partir de ponto de corte validado pela Mini International Neuropsychiatric Interview. A intensidade e a qualidade da dor nos grupos com e sem depressão foram avaliadas pelo Questionário McGill. A Escala Tampa para Cinesiofobia foi aplicada para avaliar medo do movimento. Com relação à qualidade de vida, utilizou-se o Medical Outcomes Study 36. O nível de significância estatístico estabelecido foi p< 0,05. Resultados: A prevalência de depressão foi de 32,1%. O grupo com depressão teve pior pontuação com relação à dor, cinesiofobia e qualidade de vida (capacidade funcional, aspectos físicos, dor, estado geral de saúde, vitalidade, aspectos sociais, aspectos emocionais e saúde mental). Conclusão: Pacientes com lombalgia e depressão apresentaram maior intensidade de dor, maior medo de movimento e pior qualidade de vida. Nível de Evidência III, Corte Transversal.

Objective: To describe the characteristics of pain, kinesiophobia and quality of life in patients with chronic low back pain and depression. Methods: Cross-sectional study in which 193 individuals with chronic low back pain were included. The presence of depression was measured by the Beck Depression Inventory, using a cutoff validated by the Mini International Neuropsychiatric Interview. The intensity and quality of pain in the groups with and without depression were assessed by the McGill Questionnaire. The Tampa Scale for Kinesiophobia was applied to assess fear of movement. With respect to quality of life, the Medical Outcomes Study 36 was used. The statistical significance level was set at p <0.05. Results: The prevalence of depression was 32.1%. The group with depression had worse scores in relation to pain, kinesiophobia and quality of life (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Conclusion: Patients with low back pain and depression had higher pain intensity, greater fear of movement and poorer quality of life. Level of Evidence III, Cross-sectional.

A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.

UNLABELLED: The available literature provides few studies on the effectiveness of methylphenidate in improving quality of life in individuals with ADHD. OBJECTIVE: To assess the effectiveness of methylphenidate OROS formulation (OROS MPH) through QoL in adults with ADHD. METHOD: A 12-week, multicenter, open-label trial involving 60 patients was used. The measures used were Adult Self-Rating Scale, Adult ADHD Quality of Life Scale (AAQoL), State and Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression (CGI), and safety measures. A significance statistic level of 5% was adopted. RESULTS: Analyses included 60 patients (66.7% male; M age = 31.1 years) for safety and 58 patients for effectiveness. All AAQoL subscales improved from baseline to Week 12 (p < .0001), as well as the Total AAQoL (p < .0001). A significant reduction on Clinical Global Impression-Improvement (CGI-I), HAM-D, STAI, and ASRS scores was observed (p < .0001). No serious adverse event was reported. CONCLUSION: Treatment of adult ADHD patients with OROS MPH improves QoL.

The broad autism phenotype in parents of individuals with autism: a systematic review of the literature.

The broad autism phenotype (BAP) is a milder manifestation of the defining symptoms of the syndrome in individuals without autism. This study conducted a systematic review of studies about behavioral characteristics of interpersonal relationships, communication and rigidity, as well as about three cognitive models, Theory of Mind, central coherence and executive function, in parents of individuals with autism. The indexed databases were LILACS, IBECS, Web of Science, and MEDLINE, and the studies retrieved were published between 1991 and March 2012. Parents of individuals with autism have more difficulties in interpersonal relationships and in pragmatic language use and have more rigidity traits. The inclusions of the cognitive theories in the group of BAP characteristics were inconclusive.

Pain, kinesiophobia and quality of life in chronic low back pain and depression.

OBJECTIVE: To describe the characteristics of pain, kinesiophobia and quality of life in patients with chronic low back pain and depression. METHODS: Cross-sectional study in which 193 individuals with chronic low back pain were included. The presence of depression was measured by the Beck Depression Inventory, using a cutoff validated by the Mini International Neuropsychiatric Interview. The intensity and quality of pain in the groups with and without depression were assessed by the McGill Questionnaire. The Tampa Scale for Kinesiophobia was applied to assess fear of movement. With respect to quality of life, the Medical Outcomes Study 36 was used. The statistical significance level was set at p <0.05. RESULTS: The prevalence of depression was 32.1%. The group with depression had worse scores in relation to pain, kinesiophobia and quality of life (physical functioning, rolephysical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. CONCLUSION: Patients with low back pain and depression had higher pain intensity, greater fear of movement and poorer quality of life. Level of Evidence III, Cross-sectional.

How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.

INTRODUCTION: Interview-based scales can be used as coprimary measures to complement the assessment of cognitive impairment in schizophrenia. One major question that arises from the use of such tools is how specific they are in relation to other psychopathological domains. We analyse the specificity of the Positive and Negative Syndrome Scale (PANSS) negative subscale and the Schizophrenia Cognition Rating Scale (SCoRS). METHODS: We performed a principal component analysis (PCA) of PANSS negative subscale, rated by the interviewer, and SCoRS ratings from three different sources (patient, informant, and interviewer) in 101 patients with schizophrenia. Additionally, we correlated mean SCoRS ratings to PANSS negative subscale items to determine whether any PANSS item is particularly related to cognition. RESULTS: The PCA showed that the two first components, which explained approximately 40% of the total variance of the scales, represent the SCoRS ratings and the PANSS negative subscale ratings, respectively. The mean interviewer SCoRS was significantly correlated with the PANSS negative Item 5 (difficulty in abstract thinking) and with the mean PANSS negative subscale. The latter correlation was no longer significant when "difficulty in abstract thinking" was eliminated from PANSS negative subscale. CONCLUSIONS: In general, SCoRS and PANSS negative subscale scores address different constructs; however, the PANSS negative item "difficulty in abstract thinking" seems to address a cognitive dimension.